Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | PROMISE-1: eptinezumab in episodic migraine

Messoud Ashina, MD, PhD, DMSc, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, discusses the PROMISE-1 study (NCT02559895), which evaluated the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of episodic migraine. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).